Sanofi Sarclisa SC Wins CHMP Nod for Myeloma Care
Paris, France | March 27, 2026 CHMP Recommends Innovative Subcutaneous Formulation Sanofi has achieved a major regulatory milestone as...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 Clinical Trial Phase 3 trial Precision Medicine Precision Oncology rare disease solid tumors targeted therapy
Paris, France | March 27, 2026 CHMP Recommends Innovative Subcutaneous Formulation Sanofi has achieved a major regulatory milestone as...
PARIS, FRANCE & TARRYTOWN, NEW YORK, USA | March 24, 2026 Sanofi and Regeneron have announced that Japan’s Ministry...
Paris, March 2, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug...
KINSHASA / PARIS / GENEVA / AMSTERDAM – February 27, 2026 The European Medicines Agency’s Committee for Medicinal Products...
MONTPELLIER, France | January 28, 2026 — Sensorion, a clinical-stage biotechnology company focused on hearing loss disorders, announced a...
Paris, France | December 24, 2025 — Sanofi announced that it has entered into a definitive agreement to acquire...
TARRYTOWN, N.Y. & PARIS — November 25, 2025. The European Commission has granted landmark approval for Dupixent® (dupilumab) as...
The FDA has approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax for the 2025-2026 season, targeting high-risk groups....
The FDA approved updated COVID-19 vaccines from Pfizer/BioNTech, Moderna, and Novavax while ending broad Emergency Use Authorization. Eligibility is...
AbbVie (NYSE: ABBV) has announced a definitive agreement to acquire Gilgamesh Pharmaceuticals’ lead investigational candidate bretisilocin (GM-2505), a next-generation...
